GlaxoSmithKline 1Q Missed Expectations on Pharmaceuticals, Vaccines -- Earnings Review
29 April 2021 - 12:43AM
Dow Jones News
By Cecilia Butini
GlaxoSmithKline PLC reported first-quarter earnings on
Wednesday. Here is what you need to know.
SALES: Sales came in at 7.42 billion pounds ($10.32 billion),
missing a company-provided consensus that saw them at GBP7.83
billion.
PROFIT: Glaxo's quarterly net profit of GBP1.07 billion also
missed a consensus estimate that had it at GBP1.09 billion.
WHAT WE WATCHED:
-PHARMACEUTICALS: Pharmaceuticals sales came in below consensus,
largely on HIV drugs Tivicay, Triumeq and Juluca, delivering a 5%
miss, analysts at Jefferies say. The miss is on the fact that the
first quarter of 2020 benefited strongly from stockpiling, and that
was particularly evident in the company's HIV and respiratory
portfolios, analysts at Barclays say.
-VACCINES: The division missed sales expectations by 12%,
according to Citi analysts, who note that the company's ability to
meet its guidance is likely dependent on the rebound of shingles
vaccine Shingrix, which declined 47% at constant exchange rates
during the quarter. This rebound might be hampered by the need for
Covid-19 vaccine boosters in 4Q, given constraints in administering
Shingrix in patients who need to prioritize Covid-19 shots
-GUIDANCE: The company backed its outlook as expected. An update
is expected on June 23, when the company will outline strategy and
growth outlooks from 2022 through 2031, as well as capital
allocation priorities.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
April 28, 2021 10:28 ET (14:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024